

1. (Amended) An isolated polypeptide comprising an amino acid sequence shown in SEQ ID NO:2.
5. (Amended) The polypeptide of claim 1, said polypeptide further comprising at least one conservative amino acid substitution, wherein said polypeptide is a full length polypeptide that retains functional growth factor-like properties of SEQ ID NO: 2, retains the conserved amino acids of the FGF family motif located at residues 125, 127, 129, 136, 137, 139, 141 and 148, and retains the hydrophobic transport domain between residues 92-120, wherein the residues are numbered with respect to SEQ ID NO:2.
41. (Amended) A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
46. (Amended) A kit comprising in one or more containers a composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

Add the following new claims:

63. (New) The polypeptide of claim 1, the polypeptide further comprising a post-translational modification other than a proteolytic cleavage.
64. (New) The polypeptide of claim 63, wherein the post-translational modification is at least one modification chosen from the group consisting of phosphorylation and N-myristoylation.

*Pursuant to 37 C.F.R. 1.121(c), a marked up version of the claims showing the changes made appears as Appendix B of this Amendment. As a courtesy, claims as now pending are provided in Appendix C.*